Lymphatic malformations (LMs) are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth, with more than 50% detected at birth and 90% diagnosed before the age of 2 years. The most common morbidities and serious manifestations of the disease include compression of the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional bleeding; impingement on critical structures, including nerves, vessels, lymphatics; recurrent infection; and cosmetic and other functional disabilities. There are currently no approved therapies to treat LMs.

TARA-002 is currently being evaluated in a Phase 2 open-label clinical trial for the treatment of macrocystic and mixed cystic LMs in pediatric patients. Learn more about the STARBORN-1 study and how to get involved here.